D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics

Psychopharmacology (Berl). 1989:99 Suppl:S28-31. doi: 10.1007/BF00442555.

Abstract

Using positron emission tomography and the selective ligands 11C-SCH23390 and 11C-raclopride, central D1- and D2-dopamine receptor occupancy was determined in schizophrenic patients treated with clinical doses of classical and atypical neuroleptics. Treatment with ten chemically distinct classical neuroleptics resulted in a 65-89% occupancy of D2-dopamine receptors. This finding represents strong support for the hypothesis that the mechanism of action of antipsychotic drugs is indeed related to a substantial degree of D2-dopamine receptor occupancy. In two patients treated with the atypical neuroleptic clozapine, 300 mg b.i.d. and 150 mg b.i.d., the D2-dopamine receptor occupancy was 65 and 40%, respectively. D1-dopamine receptor occupancy was determined in six antipsychotic drug-treated patients. No D1-dopamine receptor occupancy was found in patients treated with sulpiride and perphenazine, compounds known to be selective D2-dopamine receptor antagonists. The highest D1-dopamine receptor occupancy, 42%, was found in the patient treated with clozapine 150 mg b.i.d. The effects of the atypical neuroleptic clozapine may be related to a combined effect on both D1- and D2-dopamine receptors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / metabolism*
  • Antipsychotic Agents / therapeutic use
  • Basal Ganglia Diseases / chemically induced
  • Basal Ganglia Diseases / metabolism
  • Humans
  • Parkinson Disease, Secondary / chemically induced
  • Parkinson Disease, Secondary / physiopathology
  • Receptors, Dopamine / metabolism*
  • Schizophrenia / drug therapy
  • Schizophrenic Psychology

Substances

  • Antipsychotic Agents
  • Receptors, Dopamine